ACR Convergence 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences

SM

Swedish Medical Center/Providence St. Joseph Health at ACR Convergence 2026

Nov 6–11, 2026 Orlando, FL ~15k attendees Website

Swedish Medical Center/Providence St. Joseph Health brings 19 presentations to ACR Convergence 2026 in Orlando. Its program centres on psoriatic arthritis treatment, drawing on trial and registry data for drugs such as tildrakizumab, secukinumab and guselkumab. It also covers fibromyalgia treatment and teaching immunology to trainees.

OrganizationACR Convergence 2026 Attendance
SM
Swedish Medical Center/Providence St. Joseph Health
Seattle, WA
Hospitals and health systems
Affiliation spelling combines Swedish Medical Center and Providence St. Joseph Health.
Poster
Sun Nov 8
10:30am–12:30pm
Baseline Predictors of ACR Response to Tildrakizumab in Patients with Psoriatic Arthritis: An Elastic Net Analysis of Pooled Phase 3 Trials
WB1&2 · Poster 0349
Spondyloarthritis and PsA
Poster
Sun Nov 8
10:30am–12:30pm
Efficacy and Safety of Tildrakizumab in Anti-TNF-Naïve Patients With Active Psoriatic Arthritis: Week 52 Results From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
WB1&2 · Poster 0359
Spondyloarthritis and PsA
Poster
Sun Nov 8
10:30am–12:30pm
Predictors of PASI Response to Tildrakizumab: Insights from Elastic Net Modeling of Pooled Phase 3 Trials
WB1&2 · Poster 0370
Spondyloarthritis and PsA
Industry
Sun Nov 8
12:30pm–1:15pm
Managing Active PsA Across Multiple Key Domains: A Clinical Discussion on Axial Involvement
Innovation Theater A
Spondyloarthritis and PsA · Offered by Johnson & Johnson · with University of Toronto
Talk
Sun Nov 8
1:55pm–2:15pm
Part of Cellular Immunotherapy: Are We on the Cusp of a Therapeutic Revolution in Rheumatology? Session 1
Fundamentals of Teaching Immunology to Trainees and Helping Them Communicate These Concepts to Patients
Hall B, WB3 and WB4
Treatment safety
Industry
Sun Nov 8
5:30pm–7:30pm
Beyond the Joints: A Whole-Body Approach to Psoriatic Arthritis Care Through Integrated Obesity Management
Hyatt Regency Orlando, Orlando Ballroom N
Spondyloarthritis and PsA · Supported by Lilly · with University of Pennsylvania
Poster
Mon Nov 9
10:30am–12:30pm
Comparative Efficacy and Safety of Upadacitinib Versus Deucravacitinib in Biologic-Naïve Patients with Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison
WB1&2 · Poster 1309
Spondyloarthritis and PsA
Poster
Mon Nov 9
10:30am–12:30pm
Early and Sustained Improvements in Fatigue and Physical Function with Secukinumab in Patients with Psoriatic Arthritis: A Pooled Analysis of FUTURE Studies
WB1&2 · Poster 1614
Rare and other diseases
Poster
Mon Nov 9
10:30am–12:30pm
Efficacy of Izokibep, a Novel IL-17A Inhibitor, in Patients With Active Psoriatic Arthritis: Composite Measures of Disease Activity and Patient-Reported Outcomes From a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2b/3 Study
WB1&2 · Poster 1313
Spondyloarthritis and PsA
Poster
Mon Nov 9
10:30am–12:30pm
Guselkumab Response and Inhibition of Structural Damage Progression in Active Psoriatic Arthritis Across APEX Participant Subgroups
WB1&2 · Poster 1316
Spondyloarthritis and PsA
Poster
Mon Nov 9
10:30am–12:30pm
Real-World Comparative Effectiveness of Upadacitinib Versus Tumor Necrosis Factor Inhibitors or Interleukin-17 Inhibitors on Skin Symptoms in Patients With Psoriatic Arthritis
WB1&2 · Poster 1356
Spondyloarthritis and PsA
Poster
Tue Nov 10
10:30am–12:30pm
Class -Level and Drug -Level Persistence of IL-17Ai versus IL-23 Inhibitors in Psoriatic Arthritis: Results from the PPD CorEvitas PsA/SpA Registry
WB1&2 · Poster 2288
Spondyloarthritis and PsA
Poster
Tue Nov 10
10:30am–12:30pm
Comparative Effectiveness of Risankizumab Versus Tumour Necrosis Factor Inhibitors or Interleukin-17 Inhibitors on Joint Outcomes in Biologic-Naïve Patients With Psoriatic Arthritis: A Global Real-World Study
WB1&2 · Poster 2614
Rare and other diseases
Poster
Tue Nov 10
10:30am–12:30pm
Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Phase 3 Trials for PsA: Achievement of Minimal Disease Activity, Individual Components, and Very Low Disease Activity Through Week 52
WB1&2 · Poster 2291
Spondyloarthritis and PsA
Poster
Tue Nov 10
10:30am–12:30pm
Efficacy of Apremilast in Patients with Early Psoriatic Arthritis: A Post Hoc Pooled Analysis of Seven Clinical Trials
WB1&2 · Poster 2293
Spondyloarthritis and PsA
Poster
Tue Nov 10
10:30am–12:30pm
Industry
Tue Nov 10
10:30am–11:15am
What the First FDA-Approved Treatment for Fibromyalgia in Over 15 Years Means for Your Adult Patients
Innovation Theater A
Pain and fibromyalgia · Offered by Tonix Medicines · with Orthopedic Physicians of Alaska
Talk
Tue Nov 10
11:30am–12:30pm
Meet the Professor: Psoriatic Arthritis - Enrollment Required
W101A
Spondyloarthritis and PsA
Talk
Tue Nov 10
4:00pm–5:00pm
Meet the Professor: Psoriatic Arthritis - Enrollment Required
W101B
Spondyloarthritis and PsA

Explore the full ACR Convergence 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Orlando. Leave your work email and we’ll be in touch.

Privacy

Download the full ACR Convergence 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Swedish Medical Center/Providence St. Joseph Health

Tell us what you sell and we’ll find the people at Swedish Medical Center/Providence St. Joseph Health most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the American College of Rheumatology (ACR). Organization details are derived from the ACR’s published program and exhibitor floor plan, and each organization’s own website. Submit a correction